Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Faropenem

Drug Profile

Faropenem

Alternative Names: ALP 201; BLA 857; Farom; Faropenem sodium; Fropenem; FRPM; RU 67655; SUN 5555; SY 5555; WY 49605; YM 044

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Asubio Pharma
  • Developer Maruho
  • Class Antibacterials; Beta-lactams; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bacterial infections
  • No development reported Otitis media

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Otitis-media in Japan (PO)
  • 31 Mar 2015 Maruho and Banbuntane Hotokukai Hospital complete a clinical pharmacokinetics trial in Otitis media (Chronic) in Japan (PO) (UMIN000014510)
  • 16 Sep 2005 Daiichi Suntory Pharma has been acquired by Daiichi Pharmaceutical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top